Norwood Staging for Pattern Hair Loss: What Each Stage Actually Tells You matters only if it helps someone read their pattern more clearly and choose the next step with realistic expectations. Classification, timeline, and evidence beat guesswork every time.
A friend of mine, Ben, a 31-year-old software developer in Austin, texted me a top-down selfie of his scalp last October with one line: “What Norwood am I?” He’d been Googling for forty minutes. He’d landed on three different self-assessments, got three different answers, and was now oscillating between “probably fine” and “I need a transplant in Istanbul by February.” That gap between what the Norwood scale is supposed to do (give clinicians a common language) and what people actually use it for (late-night panic triage) is worth examining honestly.
So here’s the piece I wish Ben had found before texting me: what each Norwood stage indicates, how dermatologists actually use the classification, what treatment the evidence supports at each phase, and where self-assessment breaks down.
Where the Norwood Scale Came From (and Why It Still Sticks)
James Hamilton published the foundational paper on androgen-driven hair loss in the Annals of the New York Academy of Sciences in 1951. He noticed something startling: men castrated before puberty never developed the recession and crown thinning typical of androgenetic alopecia. That observation pinned male pattern hair loss to sex hormones in a way that reshaped the entire field.
Two decades later, O’Tar Norwood formalized what Hamilton had sketched. His 1975 paper in the Southern Medical Journal expanded the original three-stage framework into seven stages plus variant subtypes, including the Type A variant, where loss marches backward from the front rather than starting with the classic bitemporal recession and vertex thinning simultaneously.
Modern classification alternatives exist. The basic and specific (BASP) system proposed in 2007 aimed to capture more nuance. It hasn’t displaced Norwood in routine practice, largely because the older system hits the right tradeoff: detailed enough to be clinically useful, simple enough that two different dermatologists looking at the same scalp usually agree. That’s harder to achieve than it sounds.
The Biology That Drives Staging: DHT and Miniaturization
The Norwood stages aren’t arbitrary. They track a biological process: follicular miniaturization driven by dihydrotestosterone (DHT).
Here is the practical read: Testosterone gets converted to DHT by the 5-alpha reductase enzyme. In genetically susceptible follicles, DHT binds to androgen receptors in the dermal papilla and progressively shortens the anagen (growth) phase while lengthening the telogen (resting) phase. Over successive cycles, terminal hairs become thinner, shorter, and eventually turn into wispy, unpigmented vellus hairs. That’s miniaturization. The follicle isn’t dead. It’s just producing something functionally invisible.
The genetics are polygenic. The androgen receptor gene sits on the X chromosome (hence the maternal grandfather folklore), but paternal genes and other autosomal loci contribute meaningfully. Family history gives you a rough compass, not GPS coordinates.
This biology explains why the two main pharmacological interventions work the way they do. Finasteride blocks the type II isoform of 5-alpha reductase, lowering scalp DHT. Dutasteride blocks both type I and type II, lowering DHT more aggressively. Both approaches aim to slow or partially reverse miniaturization before the follicles are too far gone to recover.
What a Dermatology Workup Actually Looks Like
If you’re assessing yourself via bathroom mirror and iPhone flashlight, you’re working with maybe 30% of the information a dermatologist would have. That’s not nothing, but it’s not enough for decisions that matter.
A proper workup, per American Academy of Dermatology (AAD) clinical guidelines, includes patient history (timeline of loss, medications, recent illness, diet changes), family history, scalp examination, and trichoscopy. Trichoscopy is essentially dermoscopy of the scalp, and it reveals things the naked eye simply cannot: hair shaft diameter variability (caliber variability of 20% or more is characteristic of androgenetic alopecia), yellow dots indicating empty follicular ostia, decreased follicular unit density in affected areas versus the preserved occipital donor zone.
Lab work is selective, not routine. Ferritin, TSH, vitamin D, and CBC make sense when telogen effluvium is in the differential or when thinning is diffuse. The AAD does not recommend androgen panels routinely in men with classic pattern loss. The diagnosis is clinical.
Standardized photography matters more than most patients realize. Front, top, sides, and back views at consistent distance and lighting allow meaningful before-and-after comparison over six to twelve months. Without this, you’re relying on memory and confirmation bias, both of which are terrible at tracking slow changes.
Patients looking for a more detailed reference for the staging workflow can review this full explainer, which provides photographic staging examples and additional clinical context.
Treatment: What Works, What Costs, and When to Start
The single most important variable in treating pattern hair loss isn’t which drug you pick. It’s when you start. Miniaturized follicles that still have some cycling capacity can be rescued. Follicles that have gone fully dormant or scarred over cannot. This is why catching the process at Norwood II or III matters more than optimizing your topical regimen at Norwood V.
Finasteride 1 mg daily has the deepest evidence base. The original five-year randomized trial, published in the Journal of the American Academy of Dermatology (JAAD) in 2002, showed sustained improvements in hair count and self-assessment versus placebo. Sexual side effects affect a small percentage of users in randomized trials and are generally reversible on discontinuation. Generic cost: $10 to $25 per month with discount cards, sometimes $5 to $15 through telehealth platforms. Branded Propecia runs $70 to $90 monthly with no documented clinical advantage. (Just spend the savings on something useful.)
Topical minoxidil 5% applied twice daily is FDA-approved over the counter. The mechanism isn’t fully understood but involves potassium channel opening and a direct follicular effect that prolongs anagen. Visible response typically appears at three to six months. Generic cost: $10 to $30 per month. Foam and solution are clinically equivalent; foam causes less scalp irritation for some people.
Low-dose oral minoxidil (0.25 to 5 mg daily) has gained traction since a 2021 multicenter safety study by Vañó-Galván et al. in JAAD documented a manageable side-effect profile in 1,404 patients at lower doses. Periorbital edema and hypertrichosis (unwanted hair growth elsewhere) are reported. Generic cost under $15 monthly, though the prescribing visit adds $50 to $150.
Dutasteride is approved for benign prostatic hypertrophy and used off-label for hair loss. Head-to-head trials show larger DHT reductions and larger hair density improvements compared to finasteride. The side-effect conversation is similar but slightly more nuanced given the broader enzyme inhibition.
PRP and microneedling have modest evidence as adjuncts. JAMA Dermatology has published several smaller randomized trials with positive but variable results. They’re reasonable additions to medical therapy, not replacements. PRP runs $500 to $1,500 per session, with most protocols recommending three to four sessions in year one. First-year cost can exceed a full year of combination medical therapy.
Hair transplantation (FUE or FUT) is the only intervention that physically moves follicles from donor to recipient areas. In the US, FUE typically costs $4 to $10 per graft; a 2,500 to 3,500 graft case runs $10,000 to $35,000. Turkish clinics charge $2,000 to $5,000 for similar graft counts, reflecting labor cost differences rather than necessarily quality differences. It’s most appropriate when the loss pattern has stabilized and the donor area can support the extraction without looking depleted.
Insurance almost never covers any of this. HSAs and FSAs may cover prescribed medications and physician visits but typically exclude surgical procedures.
Lifestyle Factors: Separating Signal from Noise
Pattern hair loss is genetically determined. Full stop. But several lifestyle factors influence the rate and severity of shedding, and the literature (primarily JAAD and the International Journal of Trichology) draws a few clear lines.
Smoking accelerates hair loss through microvascular damage, oxidative stress, and effects on circulating androgens. Cross-sectional studies show higher androgenetic alopecia rates in smokers versus matched nonsmokers.
Iron deficiency (ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding via telogen effluvium. Repletion in deficient patients reduces shedding. Supplementation in iron-replete patients does nothing for hair density.
Severe acute stress can precipitate telogen effluvium starting two to three months after the event, typically resolving within six to nine months. The catch is that this shedding sometimes unmasks underlying pattern loss that was already progressing quietly.
Anabolic steroid use accelerates pattern hair loss in genetically susceptible men through supraphysiologic androgen exposure, with effects that may not fully reverse after discontinuation.
Severe caloric restriction, very low protein intake, and rapid weight loss all reliably produce telogen effluvium. This is one reason aggressive dieting and hair complaints so often travel together. Modest dietary improvements beyond correcting specific deficiencies don’t produce visible hair benefits. The boring truth is that a normal, adequate diet is sufficient.
When Mirror Assessment Isn’t Enough
Self-assessment is fine for monitoring a known, stable pattern. But several scenarios require in-person evaluation rather than a photo app or telehealth visit.
Sudden, diffuse shedding within the last six months points toward telogen effluvium, which needs workup of the precipitating cause, not pattern hair loss medications. Patchy, well-circumscribed bald spots suggest alopecia areata, an autoimmune condition with an entirely different treatment pathway. Scalp pain, burning, redness, scaling, or visible scarring raises the possibility of scarring alopecias like lichen planopilaris or frontal fibrosing alopecia, which require prompt diagnosis to prevent permanent follicular destruction.
In women, hair loss accompanied by menstrual irregularities, acne, or hirsutism warrants endocrine evaluation for PCOS or other androgen excess states.
Rapid progression (more than one Norwood stage per year in a young patient) and failure to respond to documented medical therapy over twelve months are both legitimate reasons to get a specialist’s eyes on your scalp, not a screen.
The AAD’s position: any progressive hair loss that concerns the patient is a valid reason for dermatology consultation. I think that’s exactly right. Anxiety about hair loss is real, and dismissing it as vanity helps nobody.
FAQs
How long does it take to see results from finasteride? Shedding typically stabilizes within three to six months. Visible regrowth, when it occurs, usually appears between six and twelve months. Full effect is assessed at one year.
Is the Norwood scale used for women? No. Female pattern hair loss is classified using the Ludwig or Savin scales, which capture the diffuse central thinning pattern more common in women.
Can pattern hair loss be reversed? Partially, in some patients, with early treatment. Combination finasteride and minoxidil started before substantial follicular dropout offers the best chance. Late-stage loss with extensive miniaturization is generally not reversible with medical therapy alone.
Is finasteride safe? Finasteride is FDA-approved at 1 mg daily for pattern hair loss and has over two decades of post-market data. Sexual side effects occur in a small percentage of users in randomized trials and are generally reversible on discontinuation. Discuss risks and benefits with a prescribing clinician.
Is oral minoxidil better than topical? Low-dose oral minoxidil produces comparable effects with better adherence for many patients. The choice depends on individual side-effect tolerance and preference, and should be made with a prescribing clinician.
What is shock loss after a hair transplant? Temporary shedding of native or transplanted hairs in the weeks following transplant surgery. It typically resolves over three to six months as follicles re-enter the growth phase.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
